| For: | Garcia JA, Alcaraz D, Holgado E, Couñago F. Pembrolizumab autoimmune related diabetes: Moving forward, keep learning. World J Clin Oncol 2024; 15(5): 576-579 [PMID: 38835848 DOI: 10.5306/wjco.v15.i5.576] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v15/i5/576.htm |
| Number | Citing Articles |
| 1 |
Jincai Guo, Yixiang Hu, Ya Liu, Yan Wang. Pembrolizumab-induced type-1 diabetes mellitus: clinical characteristics, therapeutic strategies, and prognosis from a retrospective analysis of 43 published cases. Frontiers in Endocrinology 2026; 17 doi: 10.3389/fendo.2026.1947327
|
| 2 |
Mirac Burak Tak, Zaid Munir, Ahmet Aydin. Pembrolizumab-Induced Insulin-Dependent Diabetes Mellitus in a Patient With Triple-Negative Breast Cancer: A Rare Immune-Related Adverse Event. Cureus 2024; doi: 10.7759/cureus.73049
|
| 3 |
Xipeng Zhou, Peng Jiang, Mingxiang Chen, Jiashun Chen. Tislelizumab-induced fulminant type 1 diabetes mellitus (FT1D): A case report and literature review. Medicine 2025; 104(47) doi: 10.1097/MD.0000000000046310
|